Инспра Drug photo

The description is actual on 21.10.2015

  • Latin name: Inspra
  • ATH code: C03DA04
  • Active ingredient: Eplerenon (Eplerenonum)
  • Producer: Pfizer PGM (France)


Eplerenon, monohydrate of lactose, sodium of a kroskarmelloz, microcrystallic cellulose, sodium lauryl sulfate, gipromelloza, magnesium stearate, talc, opadry yellow.

Release form

Tablets of a rhomboid form of yellow color on 25 and 50 mg in the blister in cardboard packaging, No. 30.

Pharmacological action


Pharmacodynamics and pharmacokinetics


Active ingredient of drug interferes with linkng of androgenic and progesteronovy receptors with Aldosteronum which is taking part in regulation of the ABP and development of diseases of cardiovascular system. Addition of an eplerenon to therapy of HSN leads to the predicted increase in level of Aldosteronum. Purpose of drug to patients with an acute myocardial infarction considerably reduces risk of mortality at this group of diseases. The hypotensive effect was shown on average in two weeks and in a month of continuous reception reached a maximum, and its expressiveness remained within 8–24 weeks.


Absorption of an eplerenon and its distribution in an organism happens quickly enough (Cmax is reached in 2 hours). Bioavailability — 69%. Meal does not influence absorption. Eplerenon contacts plasma blood proteins for 50%, does not contact erythrocytes. It is removed with urine (about 67%) and a stake (about 32%). An elimination half-life — about 3-5 hours.

Indications to use

In therapy of a myocardial infarction for the purpose of reduction of sudden cordial and general mortality; after a myocardial infarction in the presence of a left ventricular failure.

As a part of standard treatment CHF (chronic heart failure).


  • Liver/renal failure in a severe form;
  • Clinically expressed hyperpotassemia;
  • Individual hypersensitivity to drug;
  • Concomitant use of drugs of potassium;
  • Insufficiency of lactase, intolerance of a galactose;
  • Age till 18 flyings.

Side effects

Dizziness, headache, faint; a hyperpotassemia, an eosinophilia, sleeplessness, decrease in the ABP, fibrillation of auricles, a left ventricular failure, a myocardial infarction, cough, pharyngitis, diarrhea, nausea, a lock, cholecystitis, vomiting, a meteorism, the increased perspiration, an itch, local allergic reactions, an adynamy, an indisposition.

Inspra, application instruction

At a myocardial infarction, chronic heart failure administration of drug begin 25 mg with a dose and increase a dose to 50 mg within a month under control of potassium concentration in blood. To accept drug once a day.

Correction of a starting dosage is not required to patients of advanced age, and also patients with disturbances of easy extent of function of a liver and kidneys. Administration of drug is not connected with meal.


Cases of overdose of an eplerenon are not described. The hyperpotassemia and decrease in the ABP can be probable symptomatology of overdose.


Eplerenon is not recommended to accept along with potassium drugs as they strengthen effect of anti-hypertensive drugs. It is necessary to avoid a concomitant use of an eplerenon and lithium as the risk of development of intoxication by lithium increases. It is impossible simultaneous to appoint eplerenon with takrolimusy and cyclosporine as the risk of development of a hyperpotassemia and renal failure increases.

Neuroleptics, tricyclic antidepressants, Baclofenum and amifostin at simultaneous use with eplerenony strengthen anti-hypertensive effect. Simultaneous use of an eplerenon with glucocorticoids leads to a delay of liquid and sodium in an organism. Co-administration of an eplerenon with Trimethoprimum increases risk of emergence of a hyperpotassemia.

Terms of sale

According to the recipe.

Storage conditions

At a temperature not above 25 °C.

Period of validity

2 years.

Inspra's analogs

Coincidence on the ATH code of the 4th level:

Active ingredient and the ATH code — Dekriz, Renial, Espiro, Epletor matches.

Matches 4 – y ATH code level — Veroshpiron, Spironolactonum.

About Inspre

According to doctors Inspr's drug is rather effective. Supervision over patients after the postponed heart attack and HSN shows considerable reduction before - and afterloads on heart, slows down progressing and development of a hypertrophy of a left ventricle of heart, the ABP reduces, improves diastolic function of a ventricle, reduces developments of stagnation and hypostases of soft tissues.


  • Inspra of 50 mg No. 30 tabletkipfayzer Farmasyyutikelz
  • Inspra of 25 mg No. 30 tabletkipfayzer Farmasyyutikelz

Drugstore of IFC

  • Inspra tbl p / about 50 mg No. 30, Pfizerssha
  • Inspra tbl p / about 25 mg No. 30, Pfizerssha
to show still


  • Inspra of a tablet coated 25 mg No. 30gedeke of AG (Germany)
  • Inspra of a tablet coated 50 mg No. 30gedeke of AG (Germany)


  • Inspra of the tab. p / about 25 mg No. 30pfayzer
  • Inspra of the tab. p / about 25 mg No. 30pfayzer
Section: Cardiological Cardiovascular
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use of Inspr surely consult with the attending physician.